LPTX - Leap Therapeutics

-

$undefined

N/A

(N/A)

Leap Therapeutics NasdaqCM:LPTX Leap Therapeutics, Inc., a biopharmaceutical company, acquires and develops antibody therapies for the treatment of cancer. Its lead clinical stage drug candidate includes DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in various ongoing clinical trials for treating esophagogastric and gynecologic cancers, and colorectal cancer. The company also develops FL-501, a monoclonal antibody that inhibits GDF-15 protein that is in preclinical trial. It has an option and license agreement with Adimab, LLC and BeiGene, Ltd. to develop and commercialize DKN-01 in Asia (excluding Japan), Australia, and New Zealand. The company was formerly known as HealthCare Pharmaceuticals, Inc. and changed its name to Leap Therapeutics, Inc. in November 2015. Leap Therapeutics, Inc. was incorporated in 2011 and is based in Cambridge, Massachusetts.

Location: 47 Thorndike Street, Cambridge, MA, 02141, United States | Website: https://www.leaptx.com | Industry: Biotechnology | Sector: Healthcare


Market Cap

NaN

52 Wk Range

$ - $

Previous Close

$N/A

Open

$N/A

Day Range

N/A - N/A

Volume

N/A

Avg Volume

N/A

Enterprise Value

-31.51M

Cash

47.25M

Avg Qtr Burn

-15.07M

Short % of Float

6.89%

Insider Ownership

3.37%

Institutional Own.

49.32%

Qtr Updated

12/31/24


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date

Phase 2

Data readout

Sirexatamab (DKN-01) + Bevacizumab and Chemotherapy Details
Advanced microsatellite stable colorectal cancer

Phase 2

Update

Sirexatamab (DKN-01) +/- Paclitaxel Details
Cancer, Carcinosarcoma, Ovarian cancer, Endometrial cancer

Phase 2

Update

FL-301 Details
Cancer, Pancreatic cancer, Gastric cancer

Phase 1

Data readout

Failed

Discontinued

Sirexatamab (DKN-01) + Tislelizumab +/- CAPOX Details
Gastroesophageal junction tumors, Cancer, Gastric cancer

Failed

Discontinued